EGFR and melanoma: Specifically, the expression of METTL3 is upregulated in PLX4032-resistant melanoma cells, increasing m6A modification on EGFR mRNA, which in turn promotes EGFR protein translation efficiency, ultimately causing melanoma cells to become resistant to PLX4032 targeted therapy (Bhattarai et al., 2021).